Sat, Dec 20, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Private Equity Strategies

Movers & Shakers: Monroe Capital Shows the IPO Market Isn't Dead Yet

Friday, November 16, 2012

Monroe Capital, CEO, Ted Koenig speaks to us about his successful IPO and also announced the launch of a new health care focused effort.

By: Bailey McCann

After the Facebook IPO debacle and the failure of several other IPOs to price, some industry observers are saying that the IPO market may be dead for the foreseeable future - a familiar chorus, as few things have been pronounced dead as many times as the IPO market. However, some IPOs are still seeing successful launches, and new entrants are pricing well, indicating that the market may just be rigidly focused on quality.

One recent success story can be found in Monroe Capital Corporation. Monroe Capital Corporation is a newly formed specialty finance company that intends to focus on providing financing primarily to lower middle-market companies in the United States and Canada. The business development company announced its plan to go public in October, and shortly thereafter announced an increase in its offering size. The IPO closed successfully at the end of October with 5,000,000 shares of its common stock at a public offering price of $15.00 per share, raising approximately $75m in gross proceeds.

Robert W. Baird & Co. Incorporated, William Blair & Company, L.L.C. and Janney Montgomery Scott LLC served as joint book-running managers for the initial public offering. BB&T Capital Markets, a division of Scott & Stringfellow, LLC, and Stephens Inc. served as co-lead managers, and Ladenburg Thalmann & Co. Inc. and Wunderlich Securities, Inc. served as co-managers for the initial public offering.

"Everyone involved was pleasantly surprised with how well the process went," explains Theodore L. Koenig, President and Chief Executive Officer, Monroe Capital in an interview with Opalesque. "I was confident going in that we would see a positive reaction from the market, we have worked hard to establish our track record over the years."

Monroe Capital Corporation is affiliated with Monroe Capital LLC, a leading lender to lower middlemarket companies with over $700m in assets under management; Monroe has been one of the most active investors in the middle market, investing more than $1.5bn in over 300 transactions since its inception.

Koenig explains that prior to the offering, he was confident of the results going in as the firm went through a significant due diligence process to examine the current market and what investors were looking for in order to create an attractive offering. Monroe has offices in several major US urban centers - Charlotte, Chicago, Los Angeles and New York, which serve as a basis for a portfolio of transactions that span the country. "Our team uses these hubs as springboards to reach out to middle market companies nationwide," he says.

The company engages in a variety of transaction types including - unitranche financings; senior loans; cash flow and enterprise based term loans; acquisition facilities; mezzanine debt; second lien or last-out loans, and equity co-investments. Within that, the company has announced transactions involving a diverse group of companies. According to Koenig, what matters most for him and his team is the quality of the company and its management.

"When we are looking at a transaction, we want to see a solid management team, and recognizable value in the company. We aren't limited in geography or transaction sizes. If the quality is there, there's a deal in it for Monroe."

He notes that this approach provided the basis for the company's successful IPO in a challenging market. "A lot of our competitors are out there attempting similar offerings, but they have had a hard time differentiating their platforms; investors expect a value added approach. In order to be successful in the market right now, you have to have the platform, skills and resources to create real shareholder value because it's a buyer's market for investors - they are being more discriminating in where they place their dollars."

So far, the approach seems to be working, Monroe Capital Corporation announced a fourth quarter dividend of $0.34 per share at the beginning of this month. Koenig says they plan to continue their growth strategy through 2013.

 
This article was published in Opalesque's Private Equity Strategies our monthly research update on the global private equity landscape including all sectors and market caps.
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies


Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. Opalesque Exclusive: U.S. legal receivables fund launched in August[more]

    Benedicte Gravrand, Opalesque Geneva for New Managers: Investing in asset-backed receivables is a strategy that has been an integral part of the alternative investment space within the overall fixed income asset c

  5. Comment - High fees and low performance hit hedge funds[more]

    From FT.com: Disenchantment over high fees and lackluster performance may finally be turning the tide against hedge funds, fresh data suggest. Despite generally weak returns since the global financial crisis, hedge funds have enjoyed positive net inflows every year since 2010. This helped assets und